[{"data":1,"prerenderedAt":226},["ShallowReactive",2],{"$f1xz7rrou2jyxg":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":54,"top_diseases":80,"top_companies":110,"key_results":139,"trends":213,"previous_editions":222,"comparison":153,"highlighted_classes":223},1,"esc-2026","ESC","esc","ESC Congress 2026",2026,"Cardiology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},4742,893,164,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":4,"Phase 3":20},15,9,2,27,[22,26,29,32,35,38,40,44,47,51],{"name":23,"count":24,"share":25},"GLP1R",48,5,{"name":27,"count":28,"share":25},"SGLT2",45,{"name":30,"count":31,"share":25},"HMGCR",43,{"name":33,"count":34,"share":25},"AGTR1",42,{"name":36,"count":37,"share":25},"ADRB1",41,{"name":39,"count":37,"share":25},"TTR",{"name":41,"count":42,"share":43},"PCSK9",35,4,{"name":45,"count":46,"share":43},"β-cardiac myosin S1 domain",34,{"name":48,"count":49,"share":50},"MR",29,3,{"name":52,"count":53,"share":50},"P2Y12",28,[55,59,63,67,70,72,75,77],{"name":56,"count":57,"share":58},"Small molecules",695,78,{"name":60,"count":61,"share":62},"Peptides",86,10,{"name":64,"count":65,"share":66},"Monoclonal antibodies",59,7,{"name":68,"count":69,"share":25},"Non-antibody therapeutic proteins",47,{"name":71,"count":34,"share":25},"Carbohydrate, lipid and polymer therapeutics",{"name":73,"count":74,"share":43},"Oligonucleotide and RNA therapeutics",40,{"name":76,"count":20,"share":50},"Radiopharmaceuticals",{"name":78,"count":79,"share":4},"Vaccines",12,[81,85,89,92,95,97,101,103,106,108],{"name":82,"count":83,"share":84},"heart failure (HF)",126,14,{"name":86,"count":87,"share":88},"coronary arteriosclerosis",102,11,{"name":90,"count":91,"share":88},"myocardial infarction (MI)",101,{"name":93,"count":94,"share":66},"Atrial fibrillation (AFib)",65,{"name":96,"count":94,"share":66},"type 2 diabetes mellitus (T2DM)",{"name":98,"count":99,"share":100},"heart failure with preserved ejection fraction (HFpEF)",54,6,{"name":102,"count":69,"share":25},"hypertension (HTN)",{"name":104,"count":105,"share":25},"heart failure with reduced ejection fraction (HFrEF)",46,{"name":107,"count":28,"share":25},"acute coronary syndrome (ACS)",{"name":109,"count":37,"share":25},"amyloidotic transthyretin cardiomyopathy (ATTR-CM)",[111,115,118,121,123,126,128,130,133,136],{"name":112,"count":113,"share":114},"Bristol Myers Squibb",74,8,{"name":116,"count":117,"share":66},"Pfizer",61,{"name":119,"count":120,"share":100},"Bayer",57,{"name":122,"count":99,"share":100},"Merck",{"name":124,"count":125,"share":100},"Novartis",51,{"name":127,"count":69,"share":25},"AstraZeneca",{"name":129,"count":37,"share":25},"Novo Nordisk",{"name":131,"count":132,"share":50},"Boehringer Ingelheim",24,{"name":134,"count":135,"share":19},"Eli Lilly",18,{"name":137,"count":138,"share":19},"Takeda",17,[140,149,157,165,173,180,190,197,205],{"title":141,"drug":142,"company":144,"phase":145,"disease":146,"finding":147,"url":148},"Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial",{"name":143,"slug":143},"evolocumab","Amgen","Phase 3","atherosclerosis","Evolocumab significantly reduced the risk of any MI by 36% compared with placebo (149 [5-Yr Kaplan-Meier, 2.7%] vs 229 [5-Yr Kaplan-Meier, 4.1%]; HR 0.64, 95% CI 0.52–0.79; p\u003C0.0001).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4164",{"title":150,"drug":151,"company":153,"phase":145,"disease":154,"finding":155,"url":156},"Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials",{"name":152,"slug":152},"obicetrapib",null,"atherosclerotic disease","Monotherapy produced a -36.4% LDL-C reduction versus placebo, with 67% and 48.5% achieving LDL-C \u003C70 mg\u002FdL and \u003C55 mg\u002FdL (placebo: 21.6% and 6.7%).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4175",{"title":158,"drug":159,"company":162,"phase":145,"disease":96,"finding":163,"url":164},"HTD1801 as a multisystem cardio-kidney-metabolic therapy in type 2 diabetes: phase 3 SYMPHONY Trials demonstrate early CKM risk modification",{"name":160,"slug":161},"berberine ursodeoxycholate","berberine-ursodeoxycholate","HighTide Therapeutics","In patients with mild renal impairment, HbA1c was reduced by 0.51% vs. placebo (p\u003C0.01).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4194",{"title":166,"drug":167,"company":169,"phase":145,"disease":170,"finding":171,"url":172},"Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: Post hoc safety analysis from HELIOS-B",{"name":168,"slug":168},"vutrisiran","Alnylam Pharmaceuticals","transthyretin amyloidosis (ATTR)","Vutrisiran treatment was associated with 25% relative risk reduction of all AEs vs placebo in the overall study population (ARR: 0.75).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.1290",{"title":174,"drug":175,"company":127,"phase":145,"disease":177,"finding":178,"url":179},"Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post hoc analysis of the BaxHTN trial",{"name":176,"slug":176},"baxdrostat","resistant hypertension (RH)","Overall, serious adverse events occurred in 1.5%, 2.5% and 1.7% of patients with baxdrostat 1 mg, 2 mg and placebo, respectively, in the low dose group, and 2.5%, 4.5% and 3.7% with baxdrostat 1 mg, 2 mg and placebo, respectively, in the standard dose group.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.3044",{"title":181,"drug":182,"company":185,"phase":186,"disease":187,"finding":188,"url":189},"ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia",{"name":183,"slug":184},"ION775","ion775","Ionis Pharmaceuticals","Phase 1","hypertriglyceridemia","Corresponding mean changes in TGs were −52% (p=0.005), −68% (p=0.0007), and −68% (p=0.0007) for 30, 100, and 300 mg, respectively, versus +0.2% with pooled placebo.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4179",{"title":191,"drug":192,"company":153,"phase":186,"disease":187,"finding":195,"url":196},"HRS-7249, a small interfering RNA targeting apolipoprotein C3, in healthy subjects",{"name":193,"slug":194},"HRS-7249","hrs-7249","Treatment-emergent adverse events (AE) were reported by 34 (94.4%) subjects in the HRS-7249 group and 8 (66.7%) subjects in the placebo group, most of which were mild in severity.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4120",{"title":198,"drug":199,"company":202,"phase":186,"disease":82,"finding":203,"url":204},"Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy",{"name":200,"slug":201},"HRS-9057","hrs-9057","Hengrui Therapeutics","Treatment-emergent adverse events (TEAEs) were reported in 9 (100%), 8 (80.0%) and 6 (100%) of patients in the HRS-9057 15 mg, 30 mg, and tolvaptan groups, respectively.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.1288",{"title":206,"drug":207,"company":202,"phase":186,"disease":210,"finding":211,"url":212},"Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phase I trial",{"name":208,"slug":209},"HRS-1301","hrs-1301","dyslipidemia","The most common TEAEs in HRS-1301 group were increased white blood cell count (9.4%) and white blood cells urine positive (9.4%) in SAD, and decreased blood fibrinogen (12.1%), increased white blood cell count (9.1%) and increased bilirubin conjugated (9.1%) in MAD.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehag785.4122",{"summary":214,"bullets":216},[215],"Small molecules were the most frequent modality (78% of drug-linked abstracts). GLP1R was the most frequent target (5%). Heart failure (HF) was the most frequent disease (14%).",[217,218,219,220,221],"Bristol Myers Squibb had the largest company share (8% of drug-linked abstracts).","Peptides were the next most frequent modality (10%).","SGLT2 was the next most frequent target (5%).","Coronary arteriosclerosis was the next most frequent disease (11%).","Pfizer had the next largest company share (7%).",[],[224],{"name":225,"count":24,"share":25,"previous_count":153,"previous_share":153,"direction":153},"GLP-1 receptor drugs",1793970603072]